Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation

In this 2006 *Journal of Orthopaedic Research* paper, Krivic and colleagues sharply transected the Achilles tendon from the calcaneal bone in rats — an injury that does not heal on its own — and tested whether intraperitoneal BPC-157 could restore the tendon-to-bone interface. Doses spanning 10 micrograms, 10 nanograms, and 10 picograms per kilogram were given once daily, starting 30 minutes after surgery. Across measurement points at days 1, 4, 7, 10, 14, and 21, BPC-157 improved healing on every axis the authors measured: the Achilles functional index, biomechanical load to failure, stiffness, Young's elasticity modulus, and immunohistochemical organization of type I collagen and vascularization. A second arm of the study added 6α-methylprednisolone, which by itself worsened healing as expected; BPC-157 substantially reversed that corticosteroid-induced impairment. The paper is one of the most-cited primary sources for the claim that BPC-157 accelerates musculoskeletal soft-tissue repair.

This is a single rodent study, not a clinical trial. The injury model — sharp surgical transection in rats — does not map cleanly onto the chronic tendinopathies that drive most human use; rats are also far more permissive to soft-tissue regeneration than humans. The dose range (10 μg, 10 ng, 10 pg per kg) is wide and the paper does not isolate a clear dose–response curve, which complicates clinical translation. The authors are the same group responsible for most BPC-157 publications, so this finding has not been independently replicated by an unaffiliated laboratory. Treat the result as a strong rat signal, not as direct evidence the same effect operates in human tendon-to-bone repair.